drugset / Trial / NCT01164345
Mozobil for Autologous Stem Cell Mobilization
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate Plerixafor (MOZOBIL) plus recombinant human G-CSF (G-CSF) efficiency in mobilizing sufficient number of stem cells from Lymphoma (NHL and HL) patients for autologous transplantation.
Timeline
- Start
- 2010-06
- Primary completion
- 2015-05
- Completion
- 2015-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Plerixafor | Small molecule | 240 ug/kg | Subcutaneous |
| Background | recombinant human G-CSF | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |